The Endometriosis Treatment Market Has Witnessed Robust Growth in North America and Asia Pacific

 


Endometriosis is a chronic disease in which tissue that normally lines the uterus grows outside the uterus. It affects around five to ten per cent women of childbearing age. Endometriosis most commonly involves ovaries, fallopian tubes, and the tissue lining the pelvis. The most common symptoms include pain during urination, pain after intercourse in pelvic area, pain in lower back during menstrual period, pain in pelvic area before menstrual cycle, excessive bleeding between periods, nausea during menstrual cycle, diarrhea, fatigue, and constipation. Effective treatments, such as hormones and excision surgery, are available. The endometriosis treatment market growth is mainly driven by the increasing prevalence of endometriosis.

According to the Endometriosis Foundation of America, endometriosis affects around 200 million women worldwide and about 1 out of every 10 women in the United States. It affects women mostly in their reproductive years and can even affect adolescents who have just started to have their periods. Endometriosis is classified into four stages, such as severe, moderate, mild, and minimal, based upon the depth, extent, and exact location of the endometriosis implants, the presence and size of endometrial implants in the ovaries, and the presence and severity of scar tissue. Therefore, with increasing incidence of endometriosis, the demand for endometriosis treatment is also increasing.

For instance, in May 2019, AbbVie, in cooperation with Neurocrine Biosciences, launched ORILISSA (elagolix) 200 mg BID dose for the treatment of moderate to severe pain associated with endometriosis. Moreover, in July 2018, the U.S. Food and Drug Administration (FDA) approved elagolix (Orilissa), the first drug developed for the treatment of moderate to severe pain from endometriosis. Thus, frequent research and development activities to accelerate the development of endometriosis treatment is a major factor driving the endometriosis treatment market growth. However, lack of education and lack of awareness is a big reason endometriosis goes undetected.

The endometriosis treatment market has witnessed substantial growth in the Asia Pacific due to increasing prevalence of endometriosis in this region. According to the Endometriosis Society of India, around 25 million women in India suffer from this condition. Thus, in June 2019, Federation of Obstetrics and Gynaecological Societies of India (FOGSI) in collaboration with Bayer Zydus Pharma launched VISION to understand the current usage pattern of various therapeutic options in Endometriosis and develop an algorithm to guide doctors on care management of endometriosis, based on different patient profiles.

Significant efforts are being made to improve the methods of diagnosis, as there is a high demand for endometriosis treatment.

Comments

Post a Comment

Popular posts from this blog

The Emergence of COVID-19 to Augment Growth of the Outsourced Drug Discovery Market

Image
  With billions of dollars in research and development costs, pharmaceutical companies around the world are always looking for new ways to address their production processes in a cost-effective manner. One way to achieve this is through outsourcing drug discovery and development services. This type of service refers to the collaboration between small and large biotech and biotechnology companies to conduct research and development activities aimed at finding better solutions to the company's core chemical concerns. Outsourcing of these drug discovery services has enabled established pharmaceutical and biotechnology companies to focus on the development of new products that can bring about significant therapeutic change and provide tangible advantages to the company's shareholders. Contract research organizations manage almost all aspects of drug discovery. Market Dynamics I ncreasing demand for outsourcing analytical testing and clinical trial services, growing R&D ex...
Read more

Otoscope Market Is Gaining Major Traction with Industry Leader Otonexus Medical Technologies Introducing Ultrasound Sensor, Which Aids Middle-Ear Infection Diagnosis

Image
  An otoscope or auricular ear picker is a simple health care tool that is used to inspect the outer ear. Many health care professionals utilize otoscopes to examine ear infections during routine check-ups and to also screen for serious ear disorders. An otoscope possibly provides a more detailed view of the external ear canal and/or ear drum or eardrum. Otoscope or also referred to as auriscope is mainly used to look into eyes. The demand for these medical devices has been on a rise in the recent past. This is typically due to the fact that there is a high burden of ENT-related diseases across the globe. As per the World Health Organization (WHO), by 2050, around 2.5 billion people are estimated to have some degree of hearing loss worldwide. Similarly, there is a heavy burden of sinusitis cases. As per the Sinusitis & Allergy Wellness Center, around 30 million adults in the U.S. are impacted with sinusitis annually. Such a high prevalence of ENT disorders has accelerated the d...
Read more

The Number of Cancer Survivors Is Projected To Increase to 22.2 Million By 2030 Fostering Oncology Drug Pipeline Analysis Market

Image
  North America is estimated to dominate the global oncology drug pipeline analysis market in the near future and this is attributed to the high prevalence of cancer and increasing launch of various novel drugs with improved efficacy. According to the National Cancer Institute, as of January 2019, there were an estimated 16.9 million cancer survivors in the United States. The number of cancer survivors is projected to increase to 22.2 million by 2030. The oncology field is experiencing significant growth and this is attributed to the increasing development of various novel therapies for the treatment of cancer. For instance, in February 2021, Rhizen Pharmaceuticals AG, a clinical-stage, oncology-focused biopharma company, with a 50% stake owned by Alembic Pharmaceuticals and the rest by its Indian CEO Swaroop Vakkalanka, has announced that its the novel, next-generation PI3K-delta inhibitor Umbralisib (Ukoniq) has secured U.S. FDA accelerated approval for the treatment of blood c...
Read more